Literature DB >> 25588968

Antibiotic consumption after implementation of a procalcitonin-guided antimicrobial stewardship programme in surgical patients admitted to an intensive care unit: a retrospective before-and-after analysis.

A Hohn1, B Heising, S Hertel, G Baumgarten, M Hochreiter, S Schroeder.   

Abstract

PURPOSE: To analyse antibiotic use density (AD)--World Health Organization defined daily doses/1,000 patient-days--before and after implementation of a local antimicrobial stewardship programme (ASP) in conjunction with a procalcitonin (PCT)-guided protocol in a surgical intensive care unit (ICU).
METHODS: In this retrospective observational study, data on 2,422 ICU patients between 2010 and 2012 were analysed. In 2011, an ASP in conjunction with a PCT protocol had been introduced into clinical practice. In a multivariate analysis, hospital mortality, length of stay (LOS) in hospital and ICU LOS were adjusted for effects from effective cost weight, gender, and age. AD and changes in the use of antibiotic classes were analysed.
RESULTS: AD decreased from 1,005.0 in 2010 to 791.9 in 2012 which is a total reduction of 21.2%. Consumption of aminoglycosides, cephalosporins and quinolones showed a marked reduction, whereas the use of penicillins did not change significantly. The multivariate models revealed no relevant changes in mortality rate, ICU LOS and hospital LOS.
CONCLUSIONS: Implementation of an ASP in conjunction with a PCT protocol in 2011 was associated with a marked decrease in total AD and led to a significant change in the spectrum of antibiotics. Clinical outcomes appeared to remain unchanged over the study period.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25588968     DOI: 10.1007/s15010-014-0718-x

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  28 in total

1.  Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals.

Authors:  S K Fridkin; C D Steward; J R Edwards; E R Pryor; J E McGowan; L K Archibald; R P Gaynes; F C Tenover
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

Review 2.  An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients.

Authors:  Dimitrios K Matthaiou; Georgia Ntani; Marina Kontogiorgi; Garyfallia Poulakou; Apostolos Armaganidis; George Dimopoulos
Journal:  Intensive Care Med       Date:  2012-04-27       Impact factor: 17.440

3.  Antibiotic stewardship in Germany: a cross-sectional questionnaire survey of 355 intensive care units.

Authors:  F Maechler; F Schwab; C Geffers; E Meyer; R Leistner; P Gastmeier
Journal:  Infection       Date:  2013-10-18       Impact factor: 3.553

Review 4.  Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis.

Authors:  H Tang; T Huang; J Jing; H Shen; W Cui
Journal:  Infection       Date:  2009-10-13       Impact factor: 3.553

5.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

Review 6.  Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation.

Authors:  Daren K Heyland; Ana P Johnson; Steven C Reynolds; John Muscedere
Journal:  Crit Care Med       Date:  2011-07       Impact factor: 7.598

7.  The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings.

Authors:  Mamoon A Aldeyab; Stephan Harbarth; Nathalie Vernaz; Mary P Kearney; Michael G Scott; Feras W Darwish Elhajji; Motasem A Aldiab; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

8.  Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres.

Authors:  Paul R Rhomberg; Ronald N Jones; Helio S Sader
Journal:  Int J Antimicrob Agents       Date:  2004-01       Impact factor: 5.283

9.  Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change?

Authors:  David M Livermore; Russell Hope; Rosy Reynolds; Ruth Blackburn; Alan P Johnson; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2013-06-13       Impact factor: 5.790

10.  Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis.

Authors:  Philipp Schuetz; Matthias Briel; Mirjam Christ-Crain; Daiana Stolz; Lila Bouadma; Michel Wolff; Charles-Edouard Luyt; Jean Chastre; Florence Tubach; Kristina B Kristoffersen; Long Wei; Olaf Burkhardt; Tobias Welte; Stefan Schroeder; Vandack Nobre; Michael Tamm; Neera Bhatnagar; Heiner C Bucher; Beat Mueller
Journal:  Clin Infect Dis       Date:  2012-05-09       Impact factor: 9.079

View more
  13 in total

Review 1.  [Antibiotic stewardship : Measures for optimizing prescription of anti-infective agents].

Authors:  C Lanckohr; H Bracht
Journal:  Anaesthesist       Date:  2018-01       Impact factor: 1.041

2.  An urgent call for infectious diseases specialists.

Authors:  G Fätkenheuer; W V Kern; B Salzberger
Journal:  Infection       Date:  2016-04       Impact factor: 3.553

Review 3.  [Procalcitonin as a  tool for the assessment of successful therapy of severe sepsis : An analysis using clinical routine data].

Authors:  K F Bodmann; M Schenker; W Heinlein; M H Wilke
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-07-04       Impact factor: 0.840

Review 4.  Procalcitonin-guided antibiotic treatment in critically ill patients.

Authors:  Andreas Hohn; Bernhard Heising; Jan-Karl Schütte; Olaf Schroeder; Stefan Schröder
Journal:  Langenbecks Arch Surg       Date:  2016-06-10       Impact factor: 3.445

Review 5.  Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.

Authors:  Brenda Ng Andriolo; Regis B Andriolo; Reinaldo Salomão; Álvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2017-01-18

6.  Interprofessional Antimicrobial Stewardship Influencing Clostridioides difficile Infection: An 8-Year Study Using Antimicrobial Use Density.

Authors:  Junichi Yoshida; Tetsuya Kikuchi; Takako Ueno; Akiko Mataga; Ikuyo Asano; Kazuhiro Otani; Tetsuro Tamura; Masao Tanaka
Journal:  Infect Drug Resist       Date:  2019-11-04       Impact factor: 4.003

7.  The impact of tracheotomy on levels of procalcitonin in patients without sepsis: a prospective study.

Authors:  Xingui Dai; Chunlai Fu; Changfa Wang; Yeping Cai; Sheng'an Zhang; Wei Guo; Daibing Kuang
Journal:  Clinics (Sao Paulo)       Date:  2015-09       Impact factor: 2.365

8.  Biomarker-based diagnosis of pacemaker and implantable cardioverter defibrillator pocket infections: A prospective, multicentre, case-control evaluation.

Authors:  Carsten Lennerz; Hrvoje Vrazic; Bernhard Haller; Siegmund Braun; Tobias Petzold; Ilka Ott; Agnes Lennerz; Jonathan Michel; Patrick Blažek; Isabel Deisenhofer; Peter Whittaker; Christof Kolb
Journal:  PLoS One       Date:  2017-03-06       Impact factor: 3.240

9.  Determinants of Deescalation Failure in Critically Ill Patients with Sepsis: A Prospective Cohort Study.

Authors:  Nawal Salahuddin; Lama Amer; Mini Joseph; Alya El Hazmi; Hassan Hawa; Khalid Maghrabi
Journal:  Crit Care Res Pract       Date:  2016-07-14

10.  Adherence to a procalcitonin-guided antibiotic treatment protocol in patients with severe sepsis and septic shock.

Authors:  Andreas Hohn; Nina Balfer; Bernhard Heising; Sabine Hertel; Jan C Wiemer; Marcel Hochreiter; Stefan Schröder
Journal:  Ann Intensive Care       Date:  2018-06-04       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.